Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma

Leukemia

Volumn 23, Issue 10, 2009, Pages 1875-1884

  Schwindt, H ^a   Vater, I ^b   Kreuz, M ^c   Montesinos Rongen, M ^a   Brunn, A ^a   Richter, J ^b   Gesk, S ^b   Ammerpohl, O ^b   Wiestler, O D ^d   Hasenclever, D ^c   Deckert, M ^a   Siebert, R ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CD27 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; FAS ANTIGEN; GENE PRODUCT; HLA ANTIBODY; MESSENGER RNA; PROTEIN ARHGEF6; PROTEIN BCL 2; PROTEIN MALT1; PROTEIN MTAP; PROTEIN P15; PROTEIN P16; PROTEIN SEPT6; STAT6 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHROMOSOMAL INSTABILITY; CHROMOSOME 10Q; CHROMOSOME 12; CHROMOSOME 12P; CHROMOSOME 18Q; CHROMOSOME 19Q; CHROMOSOME 3P; CHROMOSOME 4Q; CHROMOSOME 6P; CHROMOSOME 6Q; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE INTERACTION; GENE LOCUS; GENE TARGETING; GENETIC DIFFERENCE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; UNIPARENTAL DISOMY; X CHROMOSOME;

EID: 70350114261     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.120     Document Type: Article

References (58)

1. Montesinos-Rongen M, Siebert R, Deckert M. Primary lymphoma of the central nervous system: Just DLBCL or not? Blood 2009; 113: 7-10.
2. Schlegel U, Schmidt-Wolf IG, Deckert M. Primary CNS lymphoma: Clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci 2000; 181: 1-12.
3. Deckert M, Paulus W. Malignant lymphomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). WHO Classification of Tumors Pathology and Genetics of Tumours of the Nervous System, 4th edn. IRAC: Lyon, 2007, pp. 188-192.
4. Kluin P, Deckert M, Ferry JA. Primary diffuse large B-cell lymphoma of the CNS. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, 2008, pp. 240-241.
5. Montesinos-Rongen M, Zühlke-Jenisch R, Gesk S, Martin-Subero JI, Schaller C, Van Roost D et al. Interphase cytogenetic analysis of lymphoma-associated chromosomal breakpoints in primary diffuse large B-cell lymphomas of the central nervous system. J Neuropathol Exp Neurol 2002; 61 (10): 926-933.
6. Rickert CH, Dockhorn-Dworniczak B, Simon R, Paulus W. Chromosomal imbalances in primary lymphomas of the central nervous system. Am J Pathol 1999; 155: 1445-1451.
7. Weber T, Weber RG, Kaulich K, Actor B, Meyer-Puttlitz B, Lampel S et al. Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol 2000; 10: 73-84.
8. Montesinos-Rongen M, Akasaka T, Zühlke-Jenisch R, Schaller C, Van Roost D, Wiestler OD et al. Molecular characterization of BCL6 breakpoints in primary diffuse large B-cell lymphomas of the central nervous system identifies GAPD as novel translocation partner. Brain Pathol 2003; 13: 534-538.
9. Schwindt H, Akasaka T, Zühlke-Jenisch R, Hans V, Schaller C, Klapper W et al. Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination. J Neuropathol Exp Neurol 2006; 65: 776-782.
10. Booman M, Szuhai K, Rosenwald A, Hartmann E, Kluin-Nelemans H, de Jong D et al. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: The importance of apoptosis and immunomodulatory pathways. J Pathol 2008; 216: 209-217.
11. Jordanova ES, Riemersma SA, Philippo K, Giphart-Gassler M, Schuuring E, Kluin PM. Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosomes Cancer 2002; 35: 38-48.
12. Riemersma SA, Jordanova ES, Schop RF, Philippo K, Looijenga LH, Schuuring E et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000; 96 3569-3577.
13. Brunn A, Montesinos-Rongen M, Strack A, Reifenberger G, Mawrin C, Schaller C et al. Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma. Acta Neuropathol (Berl) 2007; 114: 271-276.
14. Montesinos-Rongen M, Küppers R, Schlüter D, Spieker T, Van Roost D, Schaller C et al. Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol 1999; 155: 2077-2086.
15. Montesinos-Rongen M, Van Roost D, Schaller C, Wiestler OD, Deckert M. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 2004; 103: 1869-1875.
16. Kennedy GC, Matsuzaki H, Dong S, Liu WM, Huang J, Liu G et al. Large-scale genotyping of complex DNA. Nat Biotechnol 2003; 21 1233-1237.
17. Affymetrix. BRLMM: An improved genotype calling method for the GeneChip human mapping 500k array set. 2006, White Paper: Affymetrix Inc.
18. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A et al A robust algorithm for copy number detection using highdensity oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005; 65: 6071-6079.
19. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y et al Detection of large-scale variation in the human genome. Nat Genet 2004; 36: 949-951.
20. Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway LA et al. Inferring loss-of-heterozygosity from unpaired tumors using highdensity oligonucleotide SNP arrays. PLoS Comput Biol 2006; 2: E41.
21. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 2004; 20: 1233-1240.
22. Zhao X, Li C, Paez JG, Chin K, Janne PA, Chen TH et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 2004; 64: 3060-3071.
23. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C et al. NCBI GEO: Mining tens of millions of expression profiles - database and tools update. Nucleic Acids Res 2007; 35: D760-D765.
24. Montesinos-Rongen M, Brunn A, Bentink S, Basso K, Lim WK, Klapper W et al. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia 2008; 22: 400-405.
25. Courts C, Montesinos-Rongen M, Brunn A, Bug S, Siemer D, Hans V et al Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma. J Neuropathol Exp Neurol 2008; 67: 720-727.
26. Martin-Subero JI, Harder L, Gesk S, Schlegelberger B, Grote W, Martinez-Climent JA et al. Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. Int J Cancer 2002; 98: 470-474.
27. Tost J, Gut IG. Analysis of gene-specific DNA methylation patterns by pyrosequencing technology. Methods Mol Biol 2007; 373: 89-102.
28. Booman M, Douwes J, Glas AM, Riemersma SA, Jordanova ES, Kok K et al Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma. Clin Cancer Res 2006; 12: 2698-2705.
29. List AF, Spier CM, Miller TP, Grogan TM. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: Relationship to HLA expression and host immunocompetence. Leukemia 1993; 7: 398-403.
30. Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: A follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004; 103: 4251-4258.
31. Boonstra R, Koning A, Mastik M, van den Berg A, Poppema S. Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: Frequent loss of chromosome arm 6q. Virchows Arch 2003; 443: 164-169.
32. Bosga-Bouwer AG, Kok K, Booman M, Boven L, van der Vlies P, van den Berg A et al. Array comparative genomic hybridization reveals a very high frequency of deletions of the long arm of chromosome 6 in testicular lymphoma. Genes Chromosomes Cancer 2006; 45: 976-981.
33. Bosga-Bouwer AG, van den Berg A, Haralambieva E, de Jong D, Boonstra R, Kluin P et al. Molecular, cytogenetic, and immuno-phenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? Hum Pathol 2006; 37: 528-533.
34. Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006; 203: 311-317.
35. Thelander EF, Ichimura K, Corcoran M, Barbany G, Nordgren A, Heyman M et al. Characterization of 6q deletions in mature B cell lymphomas and childhood acute lymphoblastic leukemia. Leuk Lymphoma 2008; 49: 477-487.
36. Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 2006; 107: 4090-4100.
37. Montesinos-Rongen M, Schmitz R, Courts C, Stenzel W, Bechtel D, Niedobitek G et al. Absence of immunoglobulin class switch in primary lymphomas of the central nervous system. Am J Pathol 2005; 166: 1773-1779.
38. Aliahmad P, Kaye J. Development of all CD4T lineages requires nuclear factor TOX. J Exp Med 2008; 205: 245-256.
39. Bardet V, Couque N, Cattolico L, Hetet G, Devaux I, Duprat S et al Molecular analysis of nonrandom 8q12 deletions in acute lymphoblastic leukemia: Identification of two candidate genes. Genes Chromosomes Cancer 2002; 33: 178-187.
40. Lu SH, Takeuchi T, Fujita J, Ishida T, Akisawa Y, Nishimori I et al Effect of carbonic anhydrase-related protein VIII expression on lung adenocarcinoma cell growth. Lung Cancer 2004; 44: 273-280.
41. Morimoto K, Nishimori I, Takeuchi T, Kohsaki T, Okamoto N, Taguchi T et al. Overexpression of carbonic anhydrase-related protein XI promotes proliferation and invasion of gastrointestinal stromal tumors. Virchows Arch 2005; 447: 66-73.
42. Nishikata M, Nishimori I, Taniuchi K, Takeuchi T, Minakuchi T, Kohsaki T et al. Carbonic anhydrase-related protein VIII promotes colon cancer cell growth. Mol Carcinog 2007; 46: 208-214.
43. Haller F, Lobke C, Ruschhaupt M, Cameron S, Schulten HJ, Schwager S et al. Loss of 9p leads to p16INK4A down-regulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs). J Pathol 2008; 215: 253-262.
44. Chu LC, Eberhart CG, Grossman SA, Herman JG. Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer 2006; 119 2487-2491.
45. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
46. Fujishita T, Doi Y, Sonoshita M, Hiai H, Oshima M, Huebner K et al Development of spontaneous tumours and intestinal lesions in Fhit gene knockout mice. Br J Cancer 2004; 91: 1571-1574.
47. Kameoka Y, Tagawa H, Tsuzuki S, Karnan S, Ota A, Suguro M et al. Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma. Oncogene 2004; 23: 9148-9154.
48. Chen PM, Yang MH, Hsiao LT, Yu IT, Chu CJ, Chao TC et al. Decreased FHIT protein expression correlates with a worse prognosis in patients with diffuse large B-cell lymphoma. Oncol Rep 2004; 11 349-356.
49. Krieg AJ, Hammond EM, Giaccia AJ. Functional analysis of p53 binding under differential stresses. Mol Cell Biol 2006; 26: 7030-7045.
50. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992; 267: 10709-10715.
51. Wlodarska I, Mecucci C, Baens M, Marynen P, van den Berghe H. ETV6 gene rearrangements in hematopoietic malignant disorders. Leuk Lymphoma 1996; 23: 287-295.
52. Ferch U, zum Buschenfelde CM, Gewies A, Wegener E, Rauser S, Peschel C et al. MALT1 directs B cell receptor-induced canonical nuclear factor-kappaB signaling selectively to the c-Rel subunit. Nat Immunol 2007; 8: 984-991.
53. Courts C, Montesinos-Rongen M, Martin-Subero JI, Brunn A, Siemer D, Zühlke-Jenisch R et al. Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression. J Neuropathol Exp Neurol 2007; 66: 230-237.
54. Song Z, Krishna S, Thanos D, Strominger JL, Ono SJ. A novel cysteine-rich sequence-specific DNA-binding protein interacts with the conserved X-box motif of the human major histocompatibility complex class II genes via a repeated Cys-His domain and functions as a transcriptional repressor. J Exp Med 1994; 180: 1763-1774.
55. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA et al Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity. Cell 1995; 80: 279-284.
56. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
57. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008; 105: 13520-13525.
58. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.